文献速递呼吸危重症与机械通气

ARDS研究五十年:体外循环是否将成为ARDS管理的未来?

Fifty Years of Research in ARDS. Is Extracorporeal Circulation the Future of Acute Respiratory Distress Syndrome Management?
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

机械通气是ARDS管理的基石,但可导致呼吸机相关肺损伤。体外肺支持(ECLS)可能有两种应用场景:挽救对最大化常规通气无反应的严重低氧或高碳酸血症患者,以及替代机械通气以减轻或消除呼吸机相关肺损伤。高流量静脉-静脉ECMO可挽救最危重患者,低流量体外CO2清除可降低通气强度。ECLS在ARDS中的应用仍存争议,需高质量研究。

要点

  • 机械通气可导致呼吸机相关肺损伤,参与ARDS高死亡率。
  • 高流量VV-ECMO可挽救对常规通气无反应的严重低氧/高碳酸血症患者。
  • 低流量体外CO2清除可降低Vt至3-4 ml/kg以减轻肺损伤。

核心结论

  • ECLS在ARDS管理中有潜在价值,但应用仍存争议,需高质量研究进一步推进。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • 机械通气是ARDS管理的基石,但也可通过呼吸机相关肺损伤导致高死亡率。
  • ECLS可能用于挽救对最大化常规通气无反应的严重低氧、高碳酸血症或两者兼有的患者。
  • 高流量静脉-静脉ECMO可能挽救最危重ARDS患者。
  • 低流量体外CO2清除装置可通过降低Vt从6至3-4 ml/kg来降低通气强度。
  • 低流量体外CO2清除作为非插管、非镇静、自主呼吸患者的替代方案,可能减轻或消除呼吸机相关肺损伤。

关键数值与推荐

  • 低流量体外CO2清除可将Vt从6 ml/kg降低至3-4 ml/kg。

临床怎么用

  • 对最大化常规通气无反应的严重低氧或高碳酸血症ARDS患者,可考虑高流量VV-ECMO挽救治疗。
  • 非插管、非镇静、自主呼吸的ARDS患者,可考虑低流量体外CO2清除以降低通气强度。

局限性

  • ECLS在ARDS患者中的应用仍存争议。
  • 需要高质量研究进一步推进该领域知识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mechanical ventilation (MV) remains the cornerstone of acute respiratory distress syndrome (ARDS) management. It guarantees sufficient alveolar ventilation, high FiO2 concentration, and high positive end-expiratory pressure levels. However, experimental and clinical studies have accumulated, demonstrating that MV also contributes to the high mortality observed in patients with ARDS by creating ventilator-induced lung injury. Under these circumstances, extracorporeal lung support (ECLS) may be beneficial in two distinct clinical settings: to rescue patients from the high risk for death associated with severe hypoxemia, hypercapnia, or both not responding to maximized conventional MV, and to replace MV and minimize/abolish the harmful effects of ventilator-induced lung injury. High extracorporeal blood flow venovenous extracorporeal membrane oxygenation (ECMO) may therefore rescue the sickest patients with ARDS from the high risk for death associated with severe hypoxemia, hypercapnia, or both not responding to maximized conventional MV. Successful venovenous ECMO treatment in patients with extremely severe H1N1-associated ARDS and positive results of the CESAR trial have led to an exponential use of the technology in recent years. Alternatively, lower-flow extracorporeal CO2 removal devices may be used to reduce the intensity of MV (by reducing Vt from 6 to 3-4 ml/kg) and to minimize or even abolish the harmful effects of ventilator-induced lung injury if used as an alternative to conventional MV in nonintubated, nonsedated, and spontaneously breathing patients. Although conceptually very attractive, the use of ECLS in patients with ARDS remains controversial, and high-quality research is needed to further advance our knowledge in the field.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Combes A, Pesenti A, Ranieri VM, et al. Fifty Years of Research in ARDS. Is Extracorporeal Circulation the Future of Acute Respiratory Distress Syndrome Management? Am J Respir Crit Care Med. 2017. PMID: 28459322. doi:10.1164/rccm.201701-0217CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。